One Dose of Toad-Derived Nasal Spray Could Lift Hard-to-Treat Depression for Weeks
A Surprising Source for a Stubborn Problem
For the roughly 30 percent of people with depression who never find relief from standard antidepressants, the search for something — anything — that works can feel endless. Now, a new clinical trial is pointing toward a genuinely unexpected candidate: a psychedelic nasal spray derived from a compound found in the venom of the Sonoran Desert toad. Published in the *Journal of the American Medical Association* on October 26, 2026, the study authors concluded that “single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms.”
The active ingredient is mebufotenin, also known as 5-MeO-DMT, a psychedelic compound naturally found in the skin, venom, and eggs of the Sonoran Desert toad, also called the Colorado River toad or *Incilius alvarius*. Before anyone pictures a lick-the-toad scenario, rest assured: the compound used in the nasal spray is synthesized entirely in a laboratory, meaning no wild toad populations are harvested or harmed to produce the medication.
What the Trial Found
The study tracked 193 participants across 38 sites in Australia, Europe, and the United States between September 2023 and April 2025. Almost 200 adults aged 18 to 75 with treatment-resistant depression took part, and all had previously tried between two and five antidepressant treatments without success. Participants were randomly assigned a single dose — either 8 mg, 12 mg, or a near-inactive 0.3 mg comparison dose — and then monitored by medical staff on-site.
Patients saw their symptom scores drop by an average of 11.1 points on a 12-milligram dose and 12.5 points on an 8-milligram dose. Around one in three patients receiving the treatment also saw their depression scores fall by at least half. Perhaps most striking was how quickly and how long those benefits lasted: therapeutic efficacy persisted from day two through day 57 post-dosing, demonstrating durability without requiring prolonged clinical oversight. The 8 mg dose was selected for the next, Phase III trial because it had the best balance of safety and efficacy.
Speed Is a Major Advantage
One of the biggest practical hurdles with existing psychedelic-assisted treatments is time. Psilocybin, or magic mushrooms, typically requires patients to remain under medical supervision for over six hours, but 78% to 85% of patients receiving mebufotenin were ready for discharge within two hours of administration. That’s a significant difference — both for patients and for overstretched healthcare systems trying to make these treatments accessible.
Side effects were common across all groups, reported by roughly 73 to 85 percent of participants, but 99.7 percent of those events were mild or moderate, and no suicidal behavior occurred during the trial. The most common side effects included headache, nausea, and pain where the spray was given. One participant did experience two severe panic attacks during treatment — a reminder that psychedelic-assisted therapy, even a short-acting one, isn’t without risk.
Promising, But Not the Final Word
Researchers are careful to frame this as early-stage evidence. The study’s authors noted that many participants and clinicians could guess who received a full dose because of the drug’s noticeable psychedelic effects, and the trial did not determine how much the psychological support provided during the session contributed to the results. People with suicidal symptoms were also excluded from the study, so the safety and efficacy of mebufotenin for that group remain uncertain.
Treatment-resistant depression is a condition affecting at least 30 percent of depressed individuals who seek help — a population that has long been left with few good options. The mebufotenin nasal spray won’t be available at a pharmacy anytime soon, but with a Phase III trial now on the horizon, the science is moving fast. For millions of people who have tried drug after drug without success, a single-dose, fast-acting treatment that fits within a two-hour clinic visit represents something genuinely worth watching.


